Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biovaxys Technology Corp (OP:BVAXF)

0.1749 +0.0014 (+0.81%)
Streaming Delayed Price Updated: 12:04 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biovaxys Technology Corp

< Previous 1 2 Next >
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS
Via FinancialNewsMedia
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
Via FinancialNewsMedia
Topics Death
BIOVAXYS CANCER VACCINE MANUFACTURING PARTNER BIO ELPIDA REACHES BIOPRODUCTION MILESTONE
Via FinancialNewsMedia
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
Via FinancialNewsMedia
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
BIOVAXYS BIOPRODUCTION PARTNER WUXI BIOLOGICS COMPLETES SYNTHESIS OF RECOMBINANT SARS-COV-2 S-PROTEINS FOR BVX-0320 AND CoviDTH PROGRAMS
Via FinancialNewsMedia
FURTHER STUDY IN HUMANS SHOWS THAT THE DTH RESPONSE, THE BASIS FOR CoviDTH, IS HIGHLY DURABLE AND PERSISTS FOR AT LEAST ONE YEAR AFTER COVID-19 EXPOSURE OR VACCINE ADMINISTRATION
Via FinancialNewsMedia
Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums
Via FinancialNewsMedia
FDA PROVIDES NECESSARY GUIDANCE FOR BIOVAXYS TO BEGIN PREPARATION OF IND FOR PHASE I/II CLINICAL TRIALS OF CoviDTH
Via FinancialNewsMedia
BIOVAXYS ANNOUNCES APPOINTMENT OF POLICY ADVISOR
Via FinancialNewsMedia
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
Via FinancialNewsMedia
BIOVAXYS AND BIOELPIDA SIGN DEFINITIVE EXCLUSIVE AGREEMENT TO BEGIN OVARIAN CANCER VACCINE BIOPRODUCTION
Via FinancialNewsMedia
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.